• Recruiting

NCT03346135: Phase 2: Daratumumab After Stem Cell Transplant in Treating Patients With Myeloma NDMM

Multiple Myeloma Research Consortium

NCT03346135: Phase 2: Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma


dara post transplant

Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma


This phase II trial studies how well daratumumab after a stem cell transplant works in treating patients with multiple myeloma. Monoclonal antibodies, such as daratumumab, may kill cancer cells that are left after chemotherapy.


Sponsor:

City of Hope Medical Center


Collaborator:

National Cancer Institute (NCI)

 

ClinicalTrials.gov Identifier: NCT03346135


Official Title: A Multicenter, Open-Label, Single Arm, Phase II Study of Daratumumab as Consolidation/Maintenance Therapy After Autologous Stem Cell Transplantation in Patients With Multiple Myeloma

First Posted: November 17, 2017


https://clinicaltrials.gov/ct2/show/NCT03346135

 

Procedure: Autologous Hematopoietic Stem Cell Transplantation

Biological: Daratumumab

Other: Laboratory Biomarker Analysis

Drug: Melphalan

 


Posts Archive